8/8/2019 Protocol Procedures
1/50
Introduction to Clinical Trials
Protocols,Manual of Procedures &Data Collection
PHARMASRI www.pharmasri.com
8/8/2019 Protocol Procedures
2/50
Protocol vs Manual of Operations Analogy
PHARMASRI www.pharmasri.com
y Protocol is general blueprint fory investigators + institutional review boardsy sponsory regulatory agencies
y Manual of Procedures is detailed construction documenty clinic staff y data management staff
8/8/2019 Protocol Procedures
3/50
Desirable Protocol Characteristics
PHARMASRI www.pharmasri.com
y C lear
y C onsistent
y C omplete
8/8/2019 Protocol Procedures
4/50
S cale Implications
PHARMASRI www.pharmasri.com
y Simpley One investigator, one patient, one encounter
y
Hardery Multiple investigators, multiple patients, multiple visits,
multiple cultures, multiple languages
8/8/2019 Protocol Procedures
5/50
Considerations During ProtocolDevelopment
PHARMASRI www.pharmasri.com
For exampley R andomization assignment and outcome ascertainment
y how is potential bias minimized?
y Treatment implementationy maximize compliance while minimizing variation
y within and between investigators and clinic staff y patient and their support systemy over study follow-up and calendar time
8/8/2019 Protocol Procedures
6/50
Protocol (1)
PHARMASRI www.pharmasri.com
Should include:
1. Literature R eview (Brief)
Describe the "state of the art" and motivate rationale for this clinical trial
2. Statement of Objectivesy
What is the hypothesis that is being tested,y What endpoints or measurements & observations will be made to evaluate this therapyy e.g. BHATTo determine whether chronic administration of proprandol to pts with at least one MI will reducemortality due to all causes significantly over a 2 yr. follow up period.
y There may be more than one objective,y some primaryy some secondaryy subgroups.
3. Sample SizeAssumptions used, sources of data used & methods used to make the calculations
8/8/2019 Protocol Procedures
7/50
Protocol (2)
PHARMASRI www.pharmasri.com
4 . Study Design
a.R
ecruitmenty Entry C riteria - who are eligibley ExclusionC riteria - among those who are eligible, who should not be further considered for
various reasonsy Statement of InformedC onsent - patient must agree to all aspects of trial, particularly to those
things which will directly involve him b. R andomization Process
Description of the mechanics of how the patient is to be randomized andwhen (preferably as late as possible to avoid problems)
c. Baseline Evaluationy C linical evaluation, history, & physicaly Laboratory evaluation (e.g. EKG, X-ray, etc.)
Should describe what measurements are to be maded. Treatment Description
y Describe exactly how the two treatments are to be administered to the assigned patients, howoften, dosage, etc.
e. Follow Up Schedule & EvaluationHow often are patients to be seen, by whom & what measurementsare to be taken at each visit.
8/8/2019 Protocol Procedures
8/50
Protocol (3)
PHARMASRI www.pharmasri.com
5 . Data Monitoring
a. Toxicity: look for possible harmful effects; what variables will
be considered
b. Early Stopping: what mechanism, what endpoint will be
watched to assess whether a large early benefit has been detected, what statisticalprocedures
c. Quality C ontrol: statement of procedures to insure data
obtained is of highest quality, usually involves laboratory
results mainly
8/8/2019 Protocol Procedures
9/50
Protocol (4)
PHARMASRI www.pharmasri.com
6 . Analysis Plans
State at least what hypotheses will be tested and how in principle what statisticalmethods will be used to answer these questions.
Primary question
Secondary questions
Subgroup questions
Avoids criticism of "data dredging
Useful in pointing out potential problems in the analysis
A more detailed analysis plan can be included in an appendix or in a separate document StatisticalAnalysis Plan (SAP)
8/8/2019 Protocol Procedures
10/50
Protocol (5)
PHARMASRI www.pharmasri.com
7 . Organizational Structure
Useful because it is then clear to everyone who is in charge of what, lines of authority andwhat are the governing rules
8. List of ParticipatingC enters and Principle Investigators
"good public relations"
9. Data Monitoring &C ommittee Membership
10. Publication Policywho is acknowledged
who does the work
what is editorial processwhat is study material and what belongs to each PI
time schedule of publications
"Area most sensitive to young PI's"
8/8/2019 Protocol Procedures
11/50
PHARMASRI www.pharmasri.com
Protocol Example OutlineDiabetes Control & Complications
Trial (DCCT)
8/8/2019 Protocol Procedures
12/50
Contents (DCCT) [1]
PHARMASRI www.pharmasri.com
SUMMARY ii
SEC TION page1. INTR ODUC TION 1.1
Scope and Impact of Diabetes 1.1Background 1.3Historical Perspective 1.4F uture Directions 1.7
2. OBJEC TIVES AND DESIGN 2.1Objectives 2.1
Design 2.2
3. SAMPLE SIZE 3.1Introduction 3.1Basis of Sample SizeC alculations 3.2
8/8/2019 Protocol Procedures
13/50
Contents (DCCT) [2]
PHARMASRI www.pharmasri.com
4. PATIENT SELE
CTION AND
RE
CRUITMENT
4.1
Introduction 4 .1EligibilityC riteria 4 .1
EligibilityC riteria Applicable to BothC ategories of Subject 4 .1For Patients Without R etinopathy 4 .2For Patients With Minimal BackgroundR etinopathy 4 .3
ExclusionC riteria 4 .4
ExclusionC riteria Applicable to BothC ategories of Subject 4 .4
ExclusionC riteria for Patients WithoutR etinopathy 4 .10Additional ExclusionC riteria for Patients With MinimalBackgroundR etinopathy 4 .10
R ecruitment
5 . INF OR MEDC ONSENT 5 .1General Principles 5 .1Sequence of Procedures 5 .3
8/8/2019 Protocol Procedures
14/50
Contents (DCCT) [3]
PHARMASRI www.pharmasri.com
6 .0 PR E-R ANDOMIZATION EVALUATION 6 .1General Principles 6 .1Laboratory 6 .1Ophthalmologic 6 .2R enal 6 .2Neurologic 6 .3C ardiovascular 6 .3Psychological 6 .4C ompliance/Adherence 6 .5
Dietary 6 .6
ExaminationR esults 6 .6
Quality C ontrol 6 .6
7 .0 R ANDOMIZATION 7 .1Phase IIR andomization 7 .1C onsiderations for Phase III 7 .3Ineligible Patients Who AreR andomized 7 .4
8/8/2019 Protocol Procedures
15/50
Contents (DCCT) [4]
PHARMASRI www.pharmasri.com
8.0 METABOLIC C ONTR OLIntervention Strategy in the Standard Group 8.1
Intervention Strategy 8.1Insulin 8.3Diet 8.4
Exercise 8.5
Urine Tests 8.5
Self Blood Glucose Monitoring 8.5C linic Visits 8.6
Educational Program 8.6
Protection of Subjects 8.6
Intervention Strategy in the Experimental Group 8.7
General Guidelines 8.7
Diet 8.10Exercise 8.10Urine Tests 8.10Self Blood Glucose Monitoring 8.11C linic Visits 8.11
General Procedures to Maximize Adherence to Protocol 8.12
8/8/2019 Protocol Procedures
16/50
Contents (DCCT) [5]
PHARMASRI www.pharmasri.com
9. F OLLOW-UP PR OC EDUR ESF OR ENDPOINT VISITS 9.1General Principles 9.1Blood GlucoseC ontrol 9.1Ophthalmologic 9.2R enal 9.3Neurologic 9.3C ardiovascular 9.4
Psychological 9.4C ompliance/Adherence 9.5
Dietary 9.6ExaminationR esults 9.6
Missed Visits 9.6
Transfer 9.6
8/8/2019 Protocol Procedures
17/50
Contents (DCCT) [6]
PHARMASRI www.pharmasri.com
10. MONITOR ING PERF OR MAC E 10.1
General Principles 10.1C entral Biochemistry Laboratory & Hemoglobin Alc Laboratory 10.1C entral OphthalmologicR eading Unit 10.2
Other C entral Units 10.3
Local Procedures 10.3C linicalC enters 10.3C oordinatingC enter 10.3C orrection of Deficiencies 10.4
11. MANAGEMENT OF INTERC UR ENT EVENTS 11.1General Principles 11.1
Guidelines 11.2
8/8/2019 Protocol Procedures
18/50
Contents (DCCT) [7]
PHARMASRI www.pharmasri.com
12. DEVIATIONSFR OM ASSIGNED TR EATMENT 12.1
Introduction 12.1Deviations for Experimental Treatment 12.1
Mandatory Situations 12.1Allowable Situations 12.2Treatment Policy 12.3
Deviations from the Standard Treatment 12.4
Mandatory Situations 12.4
Allowable Situations 12.4
Treatment Policy 12.4
Transfer to Inactive Status (both treatment groups) 12.5
Procedures for Deviation or Transfer to Inactive Status 12.6
13. R ESULTS AND STATISTIC AL ANALYSIS 13.1General Principles 13.1BaselineR esults and Analyses 13.1Outcome Variables 13.2Analysis Plan 13.3Interim Analyses 13.5
8/8/2019 Protocol Procedures
19/50
Contents (DCCT) [8]
PHARMASRI www.pharmasri.com
14 . PUBLIC ATIONS AND PR ESENTATIONS 14 .1Introduction 14 .1Duties of the Publications and PresentationsC ommittee 14 .1Implementation 14 .3
15 . ANC IALLARY STUDIES 15 .1
Introduction 15
.1Definition of an Ancillary Study 15 .1R eason forR equirement Approval 15 .2
Levels of ApprovalR equired for Ancillary Studies 15 .2F unding of Ancillary StudyR esults 15 .3Publication of Ancillary StudyR esults 15 .3
Implementation 15
.4
16 . PR OTOC OL C HANGES 16 .1Introduction 16 .1Policy 16 .1Procedures 16 .1
8/8/2019 Protocol Procedures
20/50
Contents (DCCT) [9]
PHARMASRI www.pharmasri.com
17
. ADMINISTR
ATIVE STR
UC
TUR
E 17
.1Introduction 17 .1Structure 17 .1
18. DISPOSITION OF DOC UMENTS, DATA, AND MATER IALS 18.1Documents 18.1
DataF
orms 18.1Tapes of Data and AnalysisF iles 18.2Laboratory Specimens 18.2Photographs and Other Materials 18.3
Appendix page
A. A.1
B. B.1
8/8/2019 Protocol Procedures
21/50
Trial Organization
PHARMASRI www.pharmasri.com
y C omponentsy sponsory clinical centersy central resource units
y Administrationy SteeringC ommitteey Independent Data MonitoringC ommittee
y responsibilitiesy composition and independence
8/8/2019 Protocol Procedures
22/50
PHARMASRI www.pharmasri.com
Central Units(Labs, )
Clinical Centers
NIH
InstitutionalReview Board
Policy Board
Data MonitoringCommittee
SteeringCommittee
Coordinating Center
NIH Model
Patients
8/8/2019 Protocol Procedures
23/50
PHARMASRI www.pharmasri.com
Central Units(Labs, )
Clinical Centers
Patients
Data ManagementCenter (Sponsor or Contract Research
Organization)
PharmaceuticalIndustry Sponsor
InstitutionalReview Board
IndependentData Monitoring
Committee (IDMC)
SteeringCommittee
Statistical AnalysisCenter (SAC)
Regulatory Agencies
Industry-Modified NIH Model
8/8/2019 Protocol Procedures
24/50
8/8/2019 Protocol Procedures
25/50
Trial Data Collection
PHARMASRI www.pharmasri.com
y Data collection forms orC ase R eport Forms (CRF s)y Data C ompletenessy Data Integrity
Important Note: Off Treatment does not mean Off Study
8/8/2019 Protocol Procedures
26/50
Database S ize (1)
PHARMASRI www.pharmasri.com
y Number of subjectsy screenedy enrolled
y Length of follow-up/ number of subject visits
y Number central resource itemsy C entral blood measurementsy C entral pathology
8/8/2019 Protocol Procedures
27/50
Database S ize (2)
PHARMASRI www.pharmasri.com
y Number of forms/patient
y Amount of coding of free texty adverse eventsy concomitant medicationsy logs, journals, recalls, .
y C entral adjudicationy
clinical eventsy cause of deathy severity of bleeding, ...
8/8/2019 Protocol Procedures
28/50
8/8/2019 Protocol Procedures
29/50
Data Collection
PHARMASRI www.pharmasri.com
Also See MeinertR eference!
y Data collection must cover key questions or aspects1. R ecruitment Process/Eligibility Screen2. BaselineC ovariates
Who was studied? (Eligibility) Trt Balance? (C omparability)
3. C ompliance How did design get implemented?
4 . Toxicity5 . Primary and Secondary Outcomes6 . Ancillary
y Two points in time- At or before randomization- Sometime after randomization
y Most trials collect too much data!
8/8/2019 Protocol Procedures
30/50
Data CollectionRecruitment
PHARMASRI www.pharmasri.com
y Over optimismy Investigators usually overestimate number of patients they can recruit
y R ecruitment Goalsy Need to establish recruitment goals and have contingency plansy Good planning and interim monitoring
y R eview Patient Admissionsy Ask investigators to show patient admissions which meet entry criteria, if possible
y Poor R ecruitment C entery Usual reason is not enough patients screenedy If a center can't recruit effectively, it may have to be dropped from further efforts BUT
don't throw out enrolled patients
8/8/2019 Protocol Procedures
31/50
Data CollectionEligibility
PHARMASRI www.pharmasri.com
y ModifyC riteriay C hanging entry criteria doesn't usually improve recruitment that
dramatically!
y Big Nety Need to screen "10 to 20" patients for every one randomized | Big
net required
y C an't "catch upy Patient exposure to treatment lost due to lagging recruitment
8/8/2019 Protocol Procedures
32/50
B aseline Variables(On S tudy Information)
PHARMASRI www.pharmasri.com
y
All baseline data should be measured prior to randomization and start of therapy.y Uses
1. Eligibility (Based on a subset)2. Group comparability3. Stratified randomization4. Subgroup analysis5 . Establish prognostic variables
6 . Evaluate changes from baseline for outcome or toxicity7 . C omparing centers & different studies
y Timing
Should be measured as close to start of therapy as possibleMay not be able to ascertain some variablese.g. MILIS "infarct size" not possible at baseline
y May need 2 visits to confirm eligibility
8/8/2019 Protocol Procedures
33/50
Data CollectionPrimary- S econdary Outcome
PHARMASRI www.pharmasri.com
y C lear definitions
y C omplete Ascertainment
y Possible Adjudication
8/8/2019 Protocol Procedures
34/50
Data CollectionAdverse Effects
PHARMASRI www.pharmasri.com
y Many possible adverse effects may be monitored.A MultipleC omparisons Problem
y Not always as well defined (too many perhaps)y Anticipated + Unexpectedy Natural history effects
BHAT 66% placebo patients shortness of breathonly 6% at baseline had history
Need control group
y Ascertainmenty Eliciting vs. volunteer responsey Length of follow-upy F requency of patient contact
8/8/2019 Protocol Procedures
35/50
8/8/2019 Protocol Procedures
36/50
Data Collection-Quality Control (1)
PHARMASRI www.pharmasri.com
No study is better than quality of its dataFocus energy on selected key variables
Strategiesy Proper data collection formsy Data editing
a. Missing data
b.R
ange checksc. Visual inspectiond. C onsistency
8/8/2019 Protocol Procedures
37/50
a a o ec on-Quality Control (2)
PHARMASRI www.pharmasri.com
y Training/ C ertification
a. Sites b. Items- C linics - Protocol
- C entral labs - Data forms- Data center - Procedures
- Information flowy Manual of operations
-C lear definitions & instructionsy QC Procedures
- C orrect problems ASAP
8/8/2019 Protocol Procedures
38/50
Data Form Construction
PHARMASRI www.pharmasri.com
1. Need standard forms, either paper or electronic
2. Safeguards in construction
y Allow time for developing & testingy Solicit content advicey R eview other RC T forms in similar trialsy Pre-test before usingy R esearch record{ medical recordy Link each item with stated objectivey R equire adequate review before adding new items
8/8/2019 Protocol Procedures
39/50
Data Item Construction
PHARMASRI www.pharmasri.com
1. Every item should force a responseMinimize free text
2. Terminology
Keep it simpleProvide key definitions on formIf answer requires judgement or rating, provide basis
Use "yes" to indicate "presence of" (No double negative)Indicate time frame
8/8/2019 Protocol Procedures
40/50
Data Item Construction (2)
PHARMASRI www.pharmasri.com
3. Use of ExistingFormsDon't reinvent the wheel if already used elsewhereDon't use an entire form just because it existsGet permission
4 . Avoid open form - Use closed formUse response checklistSpecify units of measurement (lbs. or kg.)Enough boxes to specify adequate precision __._
Minimize calculations - obtain raw data
5 . Use STOP & SKIP instructions
8/8/2019 Protocol Procedures
41/50
Quality Assurance
PHARMASRI www.pharmasri.com
y Timely R eviewy Until recently, S.O.P. for industry was to collect data until trial was finished, then try to clean it
up or do it in batches asCR As visited sitesy Now QC can be an ongoing process
y QC Procedures
1. Visual check at clinic 6 . Periodic QA reports v feedback
2. Visual check at data center 7 . Submission of duplicate records
3. Double data entry 8. C omparison of clinics
4 . C omputer edit for admissible values 9. R e-certification of clinic personnel
5 . Data edit queries back to clinic 10. Minimize lag time patient visitp data entry
11. Audits
8/8/2019 Protocol Procedures
42/50
Data Editing
PHARMASRI www.pharmasri.com
1. Patient Identification &R ecord Linkage- Need internal check
2. Legibility
3. Form admissibility- C orrect form, correct time window
4 . Missing Information
5 . C onsistency- C onsistent answers from form to form-Within one form/section to section
6 . R anges andC ode C heck- C odes legal- R esponses within "acceptable" or "reasonable" range
8/8/2019 Protocol Procedures
43/50
Audits/Data Integrity Check
PHARMASRI www.pharmasri.com
1. C omparison of data on computer file to data form (within data center)Electronic data capture largely eliminates this problem
2.C
omparison of computer file to original medical record(at clinicalcenter)
3. Often 10% random sample used (military audit)-Do not disclose which 10% ahead of time
4 . Data center integrity
8/8/2019 Protocol Procedures
44/50
8/8/2019 Protocol Procedures
45/50
Typical Case Report Form
PHARMASRI www.pharmasri.com
8/8/2019 Protocol Procedures
46/50
PHARMASRI www.pharmasri.com
8/8/2019 Protocol Procedures
47/50
PHARMASRI www.pharmasri.com
8/8/2019 Protocol Procedures
48/50
Data Collection
PHARMASRI www.pharmasri.com
Web
E-Ma il
Da taFax
a ta lle ctiand Managemen t
O r ac lt dy e cific
a taba s e
US Ma il
Fax
Data submitted on case report forms
C linical Sites C oordinating C enter
Alternatives
Primary Method
8/8/2019 Protocol Procedures
49/50
ONCORE: A Web B ased S ystem
PHARMASRI www.pharmasri.com
y Secure, fast web based systemy Manages portfolio of cancer oriented protocolsy Many functionalities
y R eview & approvaly Subject registrationy Data collectiony Analysis
y
Started at UWCCC
, now in 15
C
entersy Local software company, Percipenzy www.oncore.org
8/8/2019 Protocol Procedures
50/50
Conclusion
PHARMASRI www.pharmasri.com
y Data collection personnel -- no matter how well-trained, careful,and proficient -- should not be expected to resolveall errors before their data are transmitted to a central database managementsite
y C entrally, someone must have big picture and also the little detailsy Not paying attention to this can be the downfall of any trial
Top Related